… at an unprecedented rate. The molecular fine-tuning of CAR T therapy, new applications of HSCT, increasing understanding … attending sessions that provided the latest updates on CAR T-cell therapies, novel strategies to treat GVHD, and …

… of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart … Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies Time and Location: Sunday, December 8, … Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas Time and …

… the current evidence about infectious complications after CAR-T therapy, with an incidence of infectious complications … between CRS and severe infections within 30-days after CAR-T reinfusion: one study identifies a double peak of IL-6 …

… booster vaccinations across different populations (HCT, CAR-T, and non-transplanted). Recommended vaccines for SARS-CoV-2 … on infectious and non-infectious complications in CAR-T cell therapy recipients. Short-term complications …

… Overall, we may expect in future more apheresises due to CAR T cell beside the hematopoietic stem cell collections. Well … Update | Chair: Marijke Quaghebeur Summary by Ruth Clout CAR-T principles and practice - Ruth Clout This session …

… Horgan : I’m a clinical research fellow in paediatric BMT, CAR-T and stem cell gene therapy at Royal Manchester Children’s … had to say no to a career opportunity because she wouldn’t be entitled to any maternity pay which seems preposterous …

… Hospital Gent opened the afternoon session about T-cell adoptive therapy. With an increasing understanding of … treatments. The next topic about CRS and neurotoxicity in CAR-T cells was presented by dr. Koen Debackere from the … and described clear the outcomes and side effects of CAR-T. Both screening tools and nursing preparation and …

… tissues and cells but also manufacturing ATMPs (including CAR-T cells) and therapeutic apheresis. I am the medical director …

… the first cellular therapy. The chimeric antigen receptor T-cell (CAR-T) treatments we have today are descendants of this … transplantation. There is also tremendous growth in the CAR-T treatments that use CD19 as a target for B-cell …

… 28/04 - Immune Effector Cells: 40 attendees 29/09 - CAR-T Cells for Inspectors: 29 attendees 24/11 - Onsite vs Remote …